文献速递骨质疏松与钙磷/甲状旁腺

地舒单抗在成骨不全儿童中的安全性与有效性——首个前瞻性对照研究

Safety and Efficacy of Denosumab in Children With Osteogenesis Imperfecta-the First Prospective Comparative Study.
PubMed 文献 · J Clin Endocrinol Metab · 2024-01-01

这项前瞻性研究将84例成骨不全儿童或青少年随机分配至地舒单抗每6个月皮下注射组或唑来膦酸单次静脉输注组,评估1年治疗期间骨密度、脊柱形态和安全性。两组骨密度及脊柱形态均显著改善,但地舒单抗组反跳性高钙血症常见且严重,14.3%达到高钙危象。作者认为地舒单抗应谨慎用于成骨不全儿童,其合适剂量和给药间隔需进一步探索。

要点

  • 地舒单抗与唑来膦酸均可显著提高成骨不全儿童骨密度并改善脊柱形态。
  • 地舒单抗组反跳性高钙血症常见且严重,14.3%达到高钙危象。
  • 地舒单抗在成骨不全儿童中应谨慎使用,其剂量和给药间隔需进一步探索。

核心结论

  • 地舒单抗或唑来膦酸治疗均有利于提高成骨不全儿童的骨密度并改善脊柱形态。
  • 地舒单抗应谨慎用于成骨不全儿童,因其反跳性高钙血症常见且危险。
  • 地舒单抗在成骨不全儿童中的合适剂量和给药间隔需进一步探索。

研究设计与样本

  • 前瞻性研究,纳入84例成骨不全儿童或青少年,随机分配至地舒单抗每6个月皮下注射组或唑来膦酸单次静脉输注组。
  • 评估1年治疗期间骨密度及其Z值、椎体形态、血清钙和骨转换标志物的变化。

主要发现

  • 治疗12个月后,地舒单抗组腰椎、股骨颈和全髋骨密度分别显著增加29.3%、27.8%和30.2%(均P < .001 vs 基线)。
  • 治疗12个月后,唑来膦酸组腰椎、股骨颈和全髋骨密度分别显著增加32.2%、47.1%和41.1%(均P < .001 vs 基线)。
  • 地舒单抗和唑来膦酸治疗后椎体高度和投影面积均显著增加。
  • 反跳性高钙血症是地舒单抗常见且严重的副作用,其中14.3%达到高钙危象。
  • 反跳性高钙血症可通过转换为唑来膦酸治疗得到缓解。

临床怎么用

  • 作者认为,地舒单抗或唑来膦酸治疗有利于提高成骨不全儿童的骨密度并改善脊柱形态。
  • 作者认为,地舒单抗应谨慎用于成骨不全儿童,因其反跳性高钙血症常见且危险。
  • 作者建议,地舒单抗在成骨不全儿童中的合适剂量和给药间隔需进一步探索。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Denosumab is a potential therapeutic agent for osteogenesis imperfecta (OI), but its efficacy and safety remain unclear in children with OI. OBJECTIVE: We aimed to investigate the effects of denosumab on bone mineral density (BMD), spinal morphometry, and safety in children with OI compared with zoledronic acid. METHODS: In this prospective study, 84 children or adolescents with OI were randomized to receive denosumab subcutaneous injection every 6 months or zoledronic acid intravenous infusion once. Changes of BMD and its Z-score, vertebral shape, serum levels of calcium and bone turnover biomarkers were assessed during the 1-year treatment. RESULTS: After 12 months of treatment, BMD at the lumbar spine, femoral neck, and total hip significantly increased by 29.3%, 27.8%, and 30.2% in the denosumab group, and by 32.2%, 47.1%, and 41.1% in the zoledronic acid group (all P < .001 vs baseline). Vertebral height and projection area significantly increased after denosumab and zoledronic acid treatment. Rebound hypercalcemia was found to be a common and serious side effect of denosumab, of which 14.3% reached hypercalcemic crisis. Rebound hypercalcemia could be alleviated by switching to zoledronic acid treatment. CONCLUSION: Treatment with denosumab or zoledronic acid is beneficial in increasing BMD and improving the spinal morphometry of children with OI. However, denosumab should be used with caution in pediatric patients with OI because of its common and dangerous side effect of rebound hypercalcemia. The appropriate dosage and dosing interval of denosumab need to be further explored in children with OI.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Liu J, Lin X, Sun L, et al. Safety and Efficacy of Denosumab in Children With Osteogenesis Imperfecta-the First Prospective Comparative Study. J Clin Endocrinol Metab. 2024. PMID: 38198649. doi:10.1210/clinem/dgad732

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。